https://wikimd.org/index.php?action=history&feed=atom&title=ARA-290ARA-290 - Revision history2026-04-27T01:06:39ZRevision history for this page on the wikiMediaWiki 1.44.2https://wikimd.org/index.php?title=ARA-290&diff=6021721&oldid=prevPrab: CSV import2024-12-01T20:43:12Z<p>CSV import</p>
<p><b>New page</b></p><div>ARA-290<br />
<br />
ARA-290 is a synthetic peptide derived from the erythropoietin (EPO) molecule, specifically designed to retain the tissue-protective properties of EPO without its erythropoietic effects. It is primarily investigated for its potential therapeutic benefits in treating chronic inflammatory and neuropathic conditions.<br />
<br />
==Structure and Mechanism of Action==<br />
<br />
ARA-290 is a small peptide that mimics the structure of the helix B surface peptide of erythropoietin. Unlike EPO, which binds to the erythropoietin receptor to stimulate red blood cell production, ARA-290 selectively interacts with the innate repair receptor (IRR), a heteromeric receptor complex formed by the β common receptor (CD131) and the erythropoietin receptor. This interaction triggers anti-inflammatory and tissue-protective signaling pathways without affecting erythropoiesis.<br />
<br />
==Therapeutic Applications==<br />
<br />
ARA-290 has been studied for its potential use in various medical conditions, including:<br />
<br />
* '''Neuropathic Pain''': ARA-290 has shown promise in reducing pain and improving nerve function in patients with small fiber neuropathy, a condition characterized by damage to small nerve fibers.<br />
<br />
* '''Diabetes''': In diabetic patients, ARA-290 may help alleviate symptoms of diabetic neuropathy and improve quality of life by reducing pain and inflammation.<br />
<br />
* '''Inflammatory Diseases''': Due to its anti-inflammatory properties, ARA-290 is being explored as a treatment for chronic inflammatory diseases, such as sarcoidosis and inflammatory bowel disease.<br />
<br />
==Clinical Trials==<br />
<br />
Several clinical trials have been conducted to evaluate the safety and efficacy of ARA-290. These studies have generally shown that ARA-290 is well-tolerated and may provide symptomatic relief in conditions like small fiber neuropathy and sarcoidosis.<br />
<br />
==Safety and Side Effects==<br />
<br />
ARA-290 is generally well-tolerated, with a favorable safety profile. Common side effects reported in clinical trials include mild injection site reactions and transient headaches. Unlike erythropoietin, ARA-290 does not increase the risk of thromboembolic events or hypertension, as it does not stimulate red blood cell production.<br />
<br />
==Future Directions==<br />
<br />
Ongoing research aims to further elucidate the mechanisms of action of ARA-290 and expand its therapeutic applications. Future studies may explore its potential in other inflammatory and neurodegenerative diseases.<br />
<br />
==Also see==<br />
<br />
* [[Erythropoietin]]<br />
* [[Neuropathic Pain]]<br />
* [[Inflammation]]<br />
* [[Diabetic Neuropathy]]<br />
<br />
{{Medical-stub}}<br />
<br />
[[Category:Peptides]]<br />
[[Category:Anti-inflammatory agents]]<br />
[[Category:Neuropathic pain treatment]]</div>Prab